Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009:2009:328364.
doi: 10.1155/2009/328364. Epub 2009 Sep 8.

Predictors of response to intradetrusor botulinum toxin-A injections in patients with idiopathic overactive bladder

Brian L Cohen  1 , Daniel J Caruso, Prashanth Kanagarajah, Angelo E Gousse
Affiliations

Predictors of response to intradetrusor botulinum toxin-A injections in patients with idiopathic overactive bladder

Brian L Cohen et al. Adv Urol. 2009.

Abstract

Objectives: To evaluate whether there are any demographic or urodynamic differences in patients with idiopathic overactive bladder (I-OAB) that respond and do not respond to intradetrusor injections of botulinum toxin-A (BTX-A).

Methods: This represents a secondary analysis of data collected from an investigator initiated randomized trial designed to evaluate clinical differences in outcomes for 100 versus 150 U BTX-A in patients with I-OAB. Preinjection demographic and urodynamic data were collected. Patients were evaluated 12 weeks after injection and were determined to be responders or nonresponders as defined by our criteria. Statistical comparisons were made between groups.

Results: In patients with overactive bladder without incontinence (OAB-Dry), there were no variables that could be used to predict response to BTX-A. On univariate analysis, younger patients with overactive bladder with incontinence (OAB-Wet) were more likely to respond to BTX-A than older patients. However, this relationship was no longer statistically significant on multivariate analysis.

Conclusions: We were unable to identify any preinjection demographic or urodynamic parameters that could aid in predicting which patients will achieve clinical response to BTX-A. Future studies are necessary to further evaluate this question.

PubMed Disclaimer

References

    1. Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU International. 2001;87(9):760–766. - PubMed
    1. Cohen BL, Tunuguntla HSG, Gousse A. Predictors of success for first stage neuromodulation: motor versus sensory response. Journal of Urology. 2006;175(6):2178–2181. - PubMed
    1. Schmid DM, Sauermann P, Werner M, et al. Experience With 100 cases treated with botulinum-a toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. Journal of Urology. 2006;176(1):177–185. - PubMed
    1. Sahai A, Khan MS, Le Gall N, Dasgupta P. Urodynamic assessment of poor responders after botulinum toxin-a treatment for overactive bladder. Urology. 2008;71(3):455–459. - PubMed
    1. Compérat E, Reitz A, Delcourt A, Capron F, Denys P, Chartier-Kastler E. Histologic features in the urinary bladder wall affected from neurogenic overactivity-a comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A. European Urology. 2006;50(5):1058–1064. - PubMed

LinkOut - more resources